Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...

Key Points It isn't easy finding high-yield dividend growth stocks when the market is at an all-time high.Shares of Novo ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Market OutlineThe Global Pharmaceutical Manufacturing Market is valued at USD 576.54 Billion in 2024 and is projected to ...

NVO shares fall 19.9% year to date amid weak CagriSema data, CEO exit and rising pressure from rivals in obesity care.

The partnership between the Danish pharmaceutical giant and the splashy telehealth firm Hims & Hers was strained from the ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

We recently published 14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price. Novo Nordisk A/S (NYSE:NVO) is ...

The investigational dual GLP-1 and amylin receptor agonist Amycretin demonstrated significant weight loss-up to 24% with ...

Amycretin is a novel, unimolecular GLP-1 and amylin receptor agonist. The aim of this study was to investigate the safety, tolerability, pharmacokinetics, and effects on bodyweight of subcutaneous ...

Researchers conducted the REDEFINE 1 and REDEFINE 2 clinical trials to assess the effect of CagriSema on weight loss in obesity with or without type 2 diabetes.

For Immediate Release Chicago, IL – July 10, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog.